ProMIS Neurosciences is trading at $11.56 (-10.66%) as broad risk-off sentiment and biotech weakness weighed on shares.
- No company-specific announcement was identified for September 24, 2026; recent coverage remains focused on conference presentations and clinical updates.
- The 10-year Treasury yield hovered near 5.14%, oil prices rose, and growth stocks faced pressure. Biotechnology also weakened, consistent with macro-sensitive sector selling.